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yotonic dystrophy (DM) is caused by two similar
noncoding repeat expansion mutations (DM1 and
DM2). It is thought that both mutations produce
pathogenic RNA molecules that accumulate in nuclear
 
foci. The DM1 mutation is a CTG expansion in the 3
 
 
 
 untrans-
lated region (3
 
 
 
-UTR) of 
 
dystrophia myotonica protein kinase
 
(
 
DMPK
 
). In a cell culture model, mutant transcripts con-
 
taining a (CUG)
 
200
 
 
 
DMPK
 
 3
 
 
 
-UTR disrupt C2C12 myoblast
differentiation; a phenotype similar to what is observed in
myoblast cultures derived from DM1 patient muscle. Here,
we have used our cell culture model to investigate how the
 
mutant 3
 
 
 
-UTR RNA disrupts differentiation. We show that
MyoD protein levels are compromised in cells that ex-
M
 
press mutant 
 
DMPK
 
 3
 
 
 
-UTR transcripts. MyoD, a transcrip-
tion factor required for the differentiation of myoblasts dur-
ing muscle regeneration, activates differentiation-speciﬁc
genes by binding E-boxes. MyoD levels are signiﬁcantly
reduced in myoblasts expressing the mutant 3
 
 
 
-UTR RNA
within the ﬁrst 6 h under differentiation conditions. This
reduction correlates with blunted E-box–mediated gene
expression at time points that are critical for initiating differ-
entiation. Importantly, restoring MyoD levels rescues the
differentiation defect. We conclude that mutant 
 
DMPK
 
3
 
 
 
-UTR transcripts disrupt myoblast differentiation by reduc-
 
ing MyoD levels below a threshold required to activate
the differentiation program.
 
Introduction
 
Myotonic dystrophy (DM)* is a common autosomal dominant
form of muscular dystrophy that shows phenotypic and genetic
heterogeneity. The distinguishing features of this disease
are myotonia (delayed muscle relaxation after a voluntary
contraction) and progressive skeletal muscle loss (Harper,
1989). Other frequent defects include cardiac arrhythmias,
cataracts, insulin resistance, and frontal balding (Harper,
1989). The severity and age of onset of these symptoms can
vary greatly from patient to patient, even within a single
family. Patients affected by congenital DM are born with
hypotonia, mental retardation, and muscle development
defects, and later develop adult DM symptoms (Harper,
1989). To date, two mutations (DM1 and DM2), at unlinked
loci, are associated with myotonic dystrophy.
The DM1 mutation, which accounts for 98% of DM
cases, is a triplet repeat (CTG) expansion on human chromo-
some 19 located in the 3
 
 
 
 untranslated region (3
 
 
 
-UTR) of a
protein kinase gene (
 
dystrophia myotonica protein kinase
 
[
 
DMPK
 
]) (Brook et al., 1992; Fu et al., 1992; Mahadevan et
al., 1992). It is not known exactly how this mutation causes
disease, but several mechanisms have been proposed (for review
see Tapscott and Thornton, 2001). These include altered
DMPK levels and/or isoforms, misexpression of neighboring
genes due to chromatin reorganization at the DM1 locus,
and a trans-dominant mutant 
 
DMPK
 
 mRNA. The DM2
mutation was recently identified as a CCTG expansion in
the first intron of the 
 
zinc finger protein 9
 
 (
 
ZNF9
 
) gene on
human chromosome 3 (Liquori et al., 2001). The similarity
of the nonprotein coding repeat expansion in both mutant
 
ZNF9
 
 and 
 
DMPK
 
 transcripts, plus the absence of genes
analogous to 
 
DMPK
 
 or its neighbors at the DM2 locus, suggest
that dominant effects mediated by CUG/CCUG expansion–
containing RNA molecules play the predominant role in
causing DM.
How the mutant RNA causes disease is under intense investi-
gation.  RNA FISH experiments show that both mutant
 
DMPK
 
 and 
 
ZNF9
 
 transcripts localize to distinct foci in the
nuclei of DM patient cells (Taneja et al., 1995; Davis et al.,
1997; Mankodi et al., 2001). It is thought that interactions
between these transcripts and RNA binding proteins result
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in the aberrant expression of other genes. Several proteins
bind the expanded 
 
DMPK
 
 3
 
 
 
-UTR RNA in vitro (Tim-
chenko et al., 1996; Lu et al., 1999; Miller et al., 2000; Tian
et al., 2000; Tiscornia and Mahadevan, 2000), and one fam-
ily of factors, MBNL, MBLL, and MBXL, colocalizes with
RNA foci in both DM1 and DM2 patient cells (Fardaei et
al., 2001, 2002; Mankodi et al., 2001). RNAs containing ex-
panded CUG tracts have been shown to skew the alternative
splicing of unrelated transcripts (Philips et al., 1998), includ-
ing the insulin receptor mRNA, which likely explains insulin
resistance seen in patients (Savkur et al., 2001). Perhaps the
most compelling evidence implicating the mutant RNA in
DM pathogenesis comes from transgenic mice that express
heterologous transcripts containing 
 
 
 
250 CUG repeats and
develop myotonia and myopathy similar to what is seen in
DM patients (Mankodi et al., 2000).
We have studied the effects of the mutant 
 
DMPK
 
 3
 
 
 
-UTR
RNA in a cell culture model. To establish this model, the
human 
 
DMPK
 
 3
 
 
 
-UTR sequence containing either a patho-
genic (CUG)
 
200
 
 repeat tract or a wild-type (CUG)
 
5
 
 tract was
fused to a reporter gene (
 
lacZ
 
 or 
 
GFP
 
) and expressed in
C2C12 mouse myoblasts (Amack et al., 1999; Amack and
Mahadevan, 2001). C2C12 are muscle precursor cells origi-
nally isolated from injured adult mouse muscle that have
proven an excellent system to study myogenic differentiation
(Yaffe and Saxel, 1977; Blau et al., 1983). When cultured in
differentiation media lacking growth factors, C2C12 cells
up-regulate muscle-specific genes, exit the cell cycle, and
fuse into multinucleated myotubes. We have shown that
transcripts containing the mutant 
 
DMPK
 
 3
 
 
 
-UTR aggregate
into nuclear foci and block C2C12 differentiation (Amack
et al., 1999). This differentiation defect may represent mus-
cle development abnormalities found in congenital DM pa-
tients (Harvey et al., 1976; Farkas-Bargeton et al., 1988)
and/or point to defects in muscle regeneration, which could
contribute to muscle wasting in adult patients. Recently, the
differentiation defect was confirmed in cultured myogenic
satellite cells taken from DM1 patients (Furling et al., 2001;
Timchenko et al., 2001).
Here, we have used our cell culture model to investigate
the molecular mechanisms that underlie how the mutant
 
DMPK
 
 3
 
 
 
-UTR RNA disrupts myoblast differentiation.
The sequence of events in the differentiation pathway has
been well characterized using C2C12 cells (Andres and
Walsh, 1996; Fig. 1 A). MyoD and Myf5 are myogenic
transcription factors expressed in committed myoblasts ca-
pable of inducing expression of myogenin and other genes
required for differentiation. After myogenin expression, cells
withdraw from the cell cycle and fuse into multinucleated
myotubes. Previous RNA analyses using our cell culture sys-
tem showed that the programmed up-regulation of 
 
myogenin
 
and 
 
p21
 
 is severely blunted in cells expressing the mutant
 
DMPK
 
 3
 
 
 
-UTR (Amack and Mahadevan, 2001). This sug-
gested that the mutant 3
 
 
 
-UTR RNA interferes with the ear-
liest stages of differentiation, perhaps by impeding the ini-
tiation of differentiation-specific gene expression. In this
report, we show that MyoD protein levels are compromised
in cells expressing mutant 
 
DMPK
 
 3
 
 
 
-UTR transcripts at
time points thought to be critical for the initiation of
C2C12 differentiation.
 
Results
 
Mutant 
 
DMPK
 
 3
 
 
 
-UTR RNA does not disable myogenic 
mechanisms downstream of myogenin
 
Myogenin is a key player in myoblast differentiation. In
mice, the lack of myogenin inhibits myoblasts from differen-
tiating into myotubes (Hasty et al., 1993; Nabeshima et al.,
1993). However, myogenic cell lines that express myogenin
and yet fail to differentiate show that defects in machinery
downstream of myogenin can also block differentiation
(Tapscott et al., 1993; Tedesco et al., 1995; Katagiri et al.,
1997). Because myogenin up-regulation is blunted in cells
expressing the mutant 
 
DMPK
 
 3
 
 
 
-UTR RNA (Amack and
Figure 1. The myogenic machinery downstream of myogenin is 
functional in cells expressing the mutant DMPK 3 -UTR. (A) The 
temporal progression of major events in the C2C12 differentiation 
pathway. Cells proliferating in growth media express MyoD and 
Myf5. When cultured in differentiation media lacking growth factors, 
cells initiate myogenin expression, exit the cell cycle, turn on muscle-
specific structural genes, such as MHC, and fuse into myotubes. 
(B) Uninfected GFP mut 3 -UTR pool (mut 3 -UTR) cells show a 
differentiation defect, and do not fuse into myotubes (stained red by 
immunofluorescent staining of MHC) as effectively as GFP wt 
3 -UTR pool (wt 3 -UTR) and control C2C12 cells. However, 
GFP mut 3 -UTR pool cells infected with a retrovirus that produces 
myogenin are capable of forming thick myotubes similar to those 
formed in GFP wt 3 -UTR pool and C2C12 cells. Infection 
with a control retrovirus that expresses LacZ has no effect on the 
differentiation phenotype. Nuclei are stained blue with DAPI. 
(C) Western blot analysis of cultures in growth media shows exogenous 
myogenin expression only in cells infected with the myogenin 
retrovirus ( myg). These blots were also probed for dynein, which 
serves as a loading control. 
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Mahadevan, 2001), we wanted to determine whether adding
exogenous myogenin is sufficient to push these cells through
differentiation, or if downstream mechanisms/molecules in
the pathway are also affected. To test this, myogenin was
overexpressed via infection with a retroviral vector carrying a
myogenin expression cassette. We tested the effects of ex-
ogenous myogenin in previously described pools of stable
C2C12 clones (Amack and Mahadevan, 2001). Pools were
generated by combining several individual clones that ex-
press 
 
GFP
 
 mRNA containing either a mutant 
 
DMPK
 
 3
 
 
 
-
UTR with 
 
 
 
200 CUG repeats (termed GFP
 
 
 
mut 3
 
 
 
-
UTR pool) or a wild-type 3
 
 
 
-UTR with five CUG repeats
(GFP
 
 
 
wt 3
 
 
 
-UTR pool).
GFP
 
 
 
mut 3
 
 
 
-UTR pool cells infected with the myogenin
retrovirus formed myotubes after 3 d in differentiation me-
dia, whereas cells infected with a control retrovirus express-
ing LacZ and uninfected cells failed to form myotubes (Fig.
1 B). Infection with the LacZ retrovirus demonstrated that
myotube formation in these cells requires myogenin and is
not simply a result of retroviral infection. The myotubes
seen in GFP
 
 
 
mut 3
 
 
 
-UTR pool cultures infected with the
myogenin retrovirus were similar to those seen in infected
control C2C12 and GFP
 
 
 
wt 3
 
 
 
-UTR pool cells, which
were larger than myotubes seen in uninfected C2C12 and
GFP
 
 
 
wt 3
 
 
 
-UTR pool populations (Fig. 1 B). RNA FISH
analysis showed that myotubes in the GFP
 
 
 
mut 3
 
 
 
-UTR
pool were foci positive (unpublished data), indicating that
expression of the mutant 
 
DMPK
 
 3
 
 
 
-UTR RNA had not
been lost. Exogenous myogenin expression in infected cells
was confirmed by Western blot analysis (Fig. 1 C), and LacZ
expression from the control retrovirus was detected by X-gal
staining (unpublished data). These results show that myoge-
nin is sufficient to correct the differentiation defect in cells
expressing the mutant 3
 
 
 
-UTR, and that mechanisms down-
stream of myogenin required for myoblast differentiation in
these cells are intact and functional.
 
MyoD protein levels are reduced in myoblasts 
expressing the mutant 
 
DMPK
 
 3
 
 
 
-UTR
 
Our next step was to investigate the effects of the mutant
 
DMPK
 
 3
 
 
 
-UTR RNA on myogenic factors that act before
myogenin induction. However, the initiation of myogenin
expression and myoblast differentiation is governed by a
complex regulatory network (for review see Puri and Sar-
torelli, 2000). Determining a priori which molecule(s) may
be affected by the mutant RNA is daunting. Fortunately, we
were presented a clue by an exceptional GFP
 
 
 
mut 3
 
 
 
-UTR
clone (termed mut 3
 
 
 
-UTR-res) that expresses the mutant
 
DMPK
 
 3 -UTR RNA, but remains capable of differentiat-
ing into myotubes (Fig. 2 A). Any number of alterations in
genetic background could account for this resistance, but
further characterization revealed that steady-state MyoD
mRNA levels were 2.6-fold higher than those in control
C2C12 populations (Fig. 2 B). MyoD protein levels are also
elevated in mut 3 -UTR-res cells, but only by 1.2-fold, as
compared with control C2C12 cells (Fig. 2 C). This hinted
to us that if increased MyoD is indeed responsible for “pro-
tecting” these myoblasts, then perhaps it is MyoD that is
compromised by the mutant DMPK RNA.
MyoD is the founding member of the myogenic regula-
tory factor (MRF) family of transcription factors that also
includes Myf5, myogenin, and MRF4 (Weintraub, 1993).
At the onset of myoblast differentiation, MyoD directly
transactivates myogenic genes, including myogenin (Hollen-
berg et al., 1993; Bergstrom et al., 2002). MyoD shares its
role in myoblast determination with Myf5, and one can
compensate for the lack of the other (Rudnicki et al., 1993).
In our cell culture model, analyses of MyoD and Myf5 ex-
pression at the RNA level revealed no consistent differences
in cells expressing the mutant DMPK 3 -UTR RNA when
compared with control C2C12 cells (Amack and Mahade-
van, 2001). However, it remained possible that MyoD and/
or Myf5 are affected at the protein level. Therefore, we first
tested whether the presence of the mutant RNA affects
MyoD or Myf5 levels in proliferating myoblasts. Western
blotting showed that both Myf5 and MyoD levels were vari-
able in each of the cell populations tested (Fig. 3). This may
be due to the fact that we assayed nonsynchronized cells in
log phase growth, during which levels of both factors fluctu-
ate with the cell cycle (Kitzmann et al., 1998; Lindon et al.,
1998). Still, densitometric quantification of MyoD, normal-
ized to a dynein loading control, showed that MyoD levels
in the GFP mut 3 -UTR pool were significantly lower
than those in control cells. The graph in Fig. 3 A shows that
Figure 2. mut 3 -UTR-res cells 
express elevated levels of MyoD. 
(A) An individual GFP mut 3 -UTR 
clone, named mut 3 -UTR-res, expresses 
mutant DMPK 3 -UTR transcripts, 
which are detected in aggregate foci 
(red) by RNA FISH, but retain the ability 
to fuse into multinucleated myotubes 
(stained green by GFP expression). 
Nuclei are stained blue with DAPI. 
(B) RNA slot blot analysis shows that 
steady-state MyoD levels are an average 
2.6-fold higher in mut 3 -UTR-res cells 
than in C2C12 cells (n   3 experiments). 
MyoD levels were normalized to gapdh 
levels. (C) Western blotting revealed 
that MyoD protein levels are elevated in mut 3 -UTR-res cells as compared with C2C12 cells, but only by an average of 1.2-fold (n   3 
experiments). MyoD protein levels were normalized to dynein.422 The Journal of Cell Biology | Volume 159, Number 3, 2002
the average MyoD level in the GFP mut 3 -UTR pool was
32% of the levels found in C2C12 and GFP wt 3 -UTR
pool cells (P   0.01; n   6 experiments). Analysis of several
individual GFP mut 3 -UTR clones (n   6) showed com-
parable results, and the average MyoD level among these
clones was 40% of the average level in C2C12 (Fig. 3 A).
There were no significant differences in Myf5 protein levels
(Fig. 3 B), indicating that the effect on MyoD has some de-
gree of specificity.
MyoD exists as a phosphoprotein that can be resolved
into hypophosphorylated and hyperphosphorylated forms
on Western blots (Fig. 3 A). The slower migrating hyper-
phosphorylated form has been shown to be a target for deg-
radation (Song et al., 1998; Kitzmann et al., 1999). It was
possible that decreased MyoD protein levels in GFP mut
3 -UTR cells were due to increased phosphorylation and
increased turnover. We examined the relative ratios of hy-
pophosphorylated versus hyperphosphorylated bands, but
found no evidence of differences between the GFP mut 3 -
UTR pool and control C2C12 cells (unpublished data). Ad-
ditionally, immunohistochemical analysis showed no differ-
ences in MyoD intracellular localization between the various
pools of cells (unpublished data).
MyoD levels are further reduced under 
differentiation conditions
Although MyoD protein levels are lower in proliferating
myoblasts that express mutant DMPK 3 -UTR transcripts,
this difference may not have deleterious consequences in
proliferating cells. The transcriptional activity of MyoD and
Myf5 is held in check until cells are stimulated to enter the
differentiation program by the removal of growth factors
(Wei and Paterson, 2001). Therefore, we characterized the
pattern of MyoD and Myf5 expression in GFP mut 3 -
UTR cells under differentiation conditions. In control
C2C12 cells, MyoD levels decreased by an average of 28%
relative to the starting levels in proliferating cells after 24 h in
differentiation media, and then remained between 50–60%
of the starting amount over the next 48 h (Fig. 4 A). A simi-
lar pattern was seen in GFP wt 3 -UTR pool cells, in which
MyoD levels decreased by 36% after 24 h. In the GFP mut
3 -UTR pool, however, the average initial drop in MyoD af-
ter 24 h was significantly greater at 72% (Fig. 4 A). MyoD
remained low at 48 h in these cells, but then rebounded by
72 h to levels similar to those in C2C12 cells (Fig. 4 A). The
sharp drop in MyoD in GFP mut 3 -UTR cells, coupled
with already low starting levels, results in nearly undetectable
levels of MyoD after 24 h in differentiation media.
Analysis of Myf5 expression revealed that concomitant
with the decrease in MyoD levels, Myf5 levels increased
 140% after 24 h in differentiation media (Fig. 4 B). This
is consistent with previous studies of MyoD and Myf5 ex-
pression patterns during the cell cycle (Kitzmann et al.,
1998; Lindon et al., 1998). Unlike our analysis of MyoD,
we found no significant differences in the Myf5 expression
pattern between GFP mut 3 -UTR pool and control cells
(Fig. 4 B), indicating that the negative effect after 24 h has
some specificity to MyoD.
Activation of E-box–mediated gene expression is 
blunted in GFP mut 3 -UTR cells
The blunted up-regulation of genes such as myogenin and
p21 in GFP mut 3 -UTR cells (Amack and Mahadevan,
2001) suggests defects in early differentiation-specific tran-
scription. MyoD and Myf5 regulate transcription at DNA
sequences (CANNTG) called E-boxes in promoter regions
of muscle-specific genes (Lassar et al., 1989). Do diminished
MyoD levels adversely affect E-box–directed gene expres-
sion, or can Myf5, which is unaffected, compensate for the
loss of MyoD? We measured E-box activation using a re-
porter construct from which expression of a luciferase gene is
Figure 3. Protein levels of MyoD, but not Myf5, are low in 
proliferating GFP mut 3 -UTR cells. (A) Despite variability, 
Western blots indicate that MyoD levels are significantly lower in 
proliferating GFP mut 3 -UTR pool (mut 3 -UTR) cells as compared 
with GFP wt 3 -UTR (wt 3 -UTR) and control C2C12 cells. Western 
blot results from six independent experiments were quantified by 
densitometry. The graph shows the average MyoD levels (normalized 
to dynein). Also shown is the average MyoD level among six 
individual GFP mut 3 -UTR clones, which is similar to the average 
in the GFP mut 3 -UTR pool. An asterisk (*) signifies a statistical 
difference (P   0.05) when compared with both C2C12 and 
GFP wt 3 -UTR pool cells. (B) Myf5 levels are also variable in 
proliferating cells, but quantification of Myf5 Western blots (n   3 
experiments) showed no significant differences among C2C12, 
GFP wt 3 -UTR pool, and GFP mut 3 -UTR pool cells. Error bars 
represent one standard deviation. Mutant DMPK 3 -UTR transcripts compromise MyoD | Amack et al. 423
driven by a thymidine kinase (TK) promoter containing
three tandem E-boxes (pE-boxLuc). To study the fold activa-
tion of E-box expression over several days, cells were cotrans-
fected with a luciferase reporter gene and a puromycin resis-
tance marker that was used to select for stable transfectants.
We determined the amount of luciferase activation that was
E-box mediated by subtracting the contribution made by the
TK promoter sequences, as measured using a control plasmid
lacking the E-boxes (pTKLuc). In transfected control C2C12
and GFP wt 3 -UTR pool cells, an average of three experi-
ments showed that E-box–luciferase expression was activated
 1.7-fold after 24 h in differentiation media and approxi-
mately twofold after 72 h (Fig. 4 C). In contrast, no activa-
tion was detected at any time point in transfected GFP mut
3 -UTR pool cells (Fig. 4 C). This suggested that the conse-
quence of reduced MyoD levels after 24 h in differentiation
media may be blunted E-box expression, and indicates that
Myf5 cannot compensate for the lack of MyoD.
MyoD protein levels and E-box activation 
are compromised within the first 6 h 
under differentiation conditions
Because each of the MRFs can transactivate E-box–contain-
ing promoters, we cannot separate out the individual contri-
butions of MyoD, Myf5, and myogenin (MRF4 is expressed
only in mature C2C12 myotubes). It is possible that the dif-
ference observed in E-box activation is due to unequal myo-
genin expression, which first starts to appear after 24 h in dif-
ferentiation media in control C2C12 and GFP wt 3 -UTR
cells, but not in GFP mut 3 -UTR cells (see Fig. 7 C, unin-
fected cells). To determine whether blunted E-box expression
correlates directly with reduced MyoD levels, we analyzed lu-
ciferase expression in transfected cultures before myogenin
expression. After 6 h in differentiation media, E-box–lucif-
erase expression was up-regulated  1.5-fold in C2C12 and
GFP wt 3 -UTR pool cells, but no up-regualtion was seen
in the GFP mut 3 -UTR pool (Fig. 5 A). This is a time
point at which no myogenin was detected by Western blot-
ting (unpublished data). Analysis of MyoD at these time
points showed that the reduction of MyoD protein levels in
GFP mut 3 -UTR pool cells occurs within 6 h of with-
drawing growth factors (Fig. 5 B). Thus, the lack of E-box–
luciferase expression in these cells correlates with reduced
MyoD levels, and, at least initially, is not due to differential
expression of myogenin. This suggests that the reduction of
MyoD results in blunted E-box–mediated gene activation.
To ensure that the 70% reduction of MyoD was a true
consequence of the mutant DMPK 3 -UTR RNA and not
an artifact specific to expression of our GFP constructs, we
next analyzed MyoD levels in another previously described
set of C2C12 clones (Amack et al., 1999). In this case, cells
either express the mutant DMPK 3 -UTR fused to a lacZ re-
porter transcript and fail to differentiate into myotubes
(lacZ 200–59), or have had expression of this RNA ablated
by a spontaneous deletion and have regained the ability to
differentiate (lacZ 200–59Rev and Cre-8). After 6 h in dif-
ferentiation media, MyoD levels decreased by 65% in
lacZ 200–59 cells, which is similar to the reduction seen in
GFP mut 3 -UTR cells (Fig. 5 C). This reduction was not
seen in lacZ 200–59Rev and Cre-8 cells, in which MyoD
expression patterns more closely resembled control C2C12
Figure 4. MyoD protein levels are reduced and E-box–luciferase activation is blunted in GFP mut 3 -UTR cells after 24 h in differentiation 
media. (A) The pattern of MyoD expression in control C2C12, GFP wt 3 -UTR pool, and GFP mut 3 -UTR pool cells cultured in differentiation 
media was analyzed by Western blots. A representative Western blot is shown, and the graph reports the average behavior of MyoD expression 
in each cell population, as determined by quantifying results from five independent experiments. MyoD levels are normalized to dynein 
levels, which do not change during differentiation, and are analyzed relative to the levels measured in proliferating cells (0 h in differentiation 
media). The difference in the MyoD expression pattern between GFP mut 3 -UTR pool cells and both C2C12 and GFP wt 3 -UTR pool 
cells is statistically significant (P   0.05) only after 24 h (*). (B) A parallel analysis of the Myf5 expression pattern revealed no statistically 
significant differences at any time point between the GFP mut 3 -UTR pool and the control C2C12 and GFP wt 3 -UTR pool populations. 
(C) A luciferase (LUC) reporter construct containing three E-boxes was used to measure E-box–mediated gene expression in control C2C12, 
GFP wt 3 -UTR pool, and GFP mut 3 -UTR pool cells. The graph shows the average fold induction of E-box–luciferase expression relative 
to luciferase levels in proliferating cells (from three independent experiments). All error bars represent one standard deviation.424 The Journal of Cell Biology | Volume 159, Number 3, 2002
cells (Fig. 5 C). These results provide additional evidence
that the presence of the mutant DMPK 3 -UTR RNA com-
promises MyoD protein levels.
MyoD reduction is posttranscriptional
To determine whether the reduction of MyoD protein is
due to transcriptional or posttranscriptional defects, we ana-
lyzed steady-state MyoD RNA levels during the first 12 h in
differentiation media. In control C2C12 cells, MyoD RNA
levels dropped to 52% of the starting levels in proliferating
cells during the first 6 h under differentiation conditions
(Fig. 6). Similar decreases were observed in GFP wt 3 -
UTR pool (46%) and GFP mut 3 -UTR pool cells (44%)
(Fig. 6). Even after 12 h there were no significant differences
in MyoD RNA levels among the three cell populations (Fig.
6). Similar results were obtained when comparing MyoD
RNA levels in the lacZ 200–59,  lacZ 200–59Rev, and
Cre-8 clones (unpublished data). This demonstrates that re-
duced MyoD protein levels in GFP mut 3 -UTR cells
within the first 6 h in differentiation media are not due to
decreased MyoD transcription or unstable MyoD mRNA.
Exogenous MyoD rescues the differentiation defect
Is increasing MyoD levels in cells that express the mutant
DMPK 3 -UTR RNA sufficient to rescue the differentiation
defect? To test this, we infected cells with a retrovirus that
produces MyoD. GFP mut 3 -UTR pool cells infected with
the MyoD retrovirus formed myotubes as effectively as in-
fected GFP wt 3 -UTR pool and control C2C12 cells after
Figure 5. E-box–luciferase activation and MyoD protein levels are 
compromised in cells expressing the mutant DMPK 3 -UTR within 
the first 6 h in differentiation media. (A) The average fold induction 
of E-box–luciferase expression in C2C12, GFP wt 3 -UTR pool, 
and GFP mut 3 -UTR pool cells during the first 24 h in differentiation 
media (from three experiments). (B) Western analysis at these time 
points revealed a significant reduction in MyoD protein levels in the 
GFP mut 3 -UTR pool as compared with control cells. The graph 
shows averaged results from three experiments. (C) Analysis of 
MyoD protein levels in lacZ 200–59 cells, which express the 
mutant DMPK 3 -UTR RNA, and lacZ 200–59Rev and Cre-8 cells, 
which have had expression of the RNA ablated, demonstrates that 
the reduction of MyoD is due to the presence of the mutant DMPK 
3 -UTR transcript. Again, the graph shows results from three 
experiments. All error bars represent one standard deviation.
Figure 6. Reduced MyoD protein levels in GFP mut 3 -UTR cells 
do not result from differential MyoD transcription or RNA stability. 
MyoD expression in control C2C12 cells, the GFP wt 3 -UTR pool, 
and the GFP mut 3 -UTR pool after 0, 6, and 12 h in differentiation 
media were analyzed on Northern blots and RNA slot blots. A 
Northern blot is shown, and the graph shows the behavior of MyoD 
steady-state RNA levels (normalized to gapdh levels) after 6 and 12 h 
in differentiation media relative to levels present in proliferating 
cells. These results were quantified from three slot blot experiments. Mutant DMPK 3 -UTR transcripts compromise MyoD | Amack et al. 425
3 d in differentiation media (Fig. 7 A). This was also observed
in several individual GFP mut 3 -UTR clones and in
lacZ 200–59 cells (unpublished data). As shown previously,
infection with the LacZ control retrovirus had no effect on
differentiation. Myotubes in GFP mut 3 -UTR cultures in-
fected with the MyoD retrovirus were RNA foci positive, in-
dicating that MyoD acts by overriding the effects of the mu-
tant RNA rather than by silencing its expression (unpublished
data). Western blotting confirmed elevated MyoD expression
in these cells to levels similar to those found in uninfected
C2C12 and GFP wt 3 -UTR cells (Fig. 7 B). Western blots
also showed that the defect in myogenin up-regulation in
GFP mut 3 -UTR pool cells was corrected by increased lev-
els of MyoD (Fig. 7 C). In fact, infected GFP mut 3 -UTR
cells show accelerated myogenin expression, similar to that
seen in infected control C2C12 and GFP wt 3 -UTR cells
(Fig. 7 C). These results, which are consistent with mut 3 -
UTR-res cells, demonstrate that increasing levels of MyoD is
sufficient to override the deleterious effects of the mutant
DMPK 3 -UTR and rescue the differentiation defect.
Discussion
We have used a malleable cell culture system to investigate
the molecular basis for how RNA molecules containing
DMPK 3 -UTR sequences with 200 CUG repeats interfere
with myoblast differentiation. Recently, it was discovered
that myoblasts isolated from DM1 patients show differentia-
tion defects similar to those we have observed in our cell cul-
ture system (Furling et al., 2001; Timchenko et al., 2001).
Using primary skeletal muscle cell lines from DM patients,
Timchenko et al. (2001) found that p21 up-regulation and
cell cycle withdrawal are compromised. However, this study
did not analyze earlier myogenic events such as myogenin
induction, which occurs before cell cycle withdrawal in
C2C12 cells (Andres and Walsh, 1996). Because myogenin
is not properly up-regulated in cells that express mutant
DMPK 3 -UTR in our model system, we have focused on
the affects of the mutant RNA on the earliest stages in the
myogenic pathway. To be sure we were looking in the right
place, we tested whether the machinery downstream of myo-
genin was functional in these cells. Ectopic myogenin ex-
pression enabled cells to overcome the deleterious effects of
mutant 3 -UTR transcripts and effectively fuse into myo-
tubes (Fig. 1 B), indicating that downstream myogenic mol-
ecules and cascades are capable of responding to myogenin
and properly regulating differentiation. This led us to hy-
pothesize that the mutant 3 -UTR RNA may compromise
upstream factor(s) involved in the induction of myogenin
and other early differentiation genes.
MyoD is compromised by mutant DMPK 3 -UTR RNA
Genetic studies using knock-out mice have placed MyoD
and Myf5 upstream of myogenin (for review see Rudnicki
and Jaenisch, 1995). This made MyoD and Myf5 candidate
targets of the mutant DMPK RNA, but there are several
other factors and signaling cascades that help regulate the
initiation of the differentiation pathway (Puri and Sartorelli,
2000). Fortunately, analysis of C2C12 myoblasts resistant to
the effects of the mutant DMPK 3  -UTR RNA demon-
strated that MyoD is overexpressed in these cells, providing
us with a hint that MyoD levels may be linked to the RNA-
mediated block of differentiation. Although MyoD mRNA
levels are not affected by mutant DMPK 3 -UTR transcripts
in our cell culture system (Amack and Mahadevan, 2001),
we investigated whether MyoD protein levels were altered in
proliferating or differentiating myoblasts. We have identi-
fied two separate effects on MyoD protein levels in cells ex-
pressing the mutant 3 -UTR. First, MyoD levels in prolifer-
ating GFP mut 3 -UTR cells were approximately three
Figure 7. Exogenous MyoD rescues the differentiation defect in cells 
expressing the mutant DMPK 3 -UTR RNA. (A) GFP mut 3 -UTR pool 
cells infected with a retrovirus that expresses MyoD regain the ability to 
form myotubes (stained red by immunofluorescent staining of MHC) as 
effectively as infected control C2C12 and GFP wt 3 -UTR pool 
cultures. Nuclei are stained blue with DAPI. (B) Western blotting shows 
increased expression of MyoD protein in proliferating cells infected with 
the MyoD retrovirus. The graph shows relative MyoD levels (normalized to dynein) in infected and uninfected cells. Similar results were 
seen in three separate infections. (C) Analysis of myogenin protein expression in infected and uninfected cells cultured in differentiation 
media shows that exogenous MyoD expression corrects the defect in myogenin up-regulation in GFP mut 3 -UTR pool cells.426 The Journal of Cell Biology | Volume 159, Number 3, 2002
times lower than in control cells (Fig. 3 A). Second, MyoD
levels were reduced an additional  70% in these cells dur-
ing the first 24 h in differentiation media, as compared with
only an  30% decrease in control C2C12 and GFP wt 3 -
UTR cells (Fig. 4 A; Fig. 5 B). No significant differences
were found in Myf5 protein levels at either time point, indi-
cating that these negative effects have some specificity for
MyoD, and are not due to a general effect on protein levels.
MyoD levels are also reduced in cells expressing a (CUG)200
DMPK 3 -UTR fused to a lacZ transcript (lacZ 200–59
cells). Significantly, this affect is abrogated when expression
of the RNA is silenced (Fig. 5 C). Taken together, these re-
sults demonstrate that the presence of DMPK 3 -UTR tran-
scripts containing 200 CUG repeats, but not five CUG re-
peats, compromises MyoD protein levels.
The loss of MyoD function has been studied using
MyoD
 /  mice. Cultured MyoD
 /  myoblasts show differ-
entiation defects and blunted up-regulation of differentiation-
specific genes (Sabourin et al., 1999; Cornelison et al., 2000),
a phenotype strikingly similar to what we observe in cells ex-
pressing the mutant 3 -UTR. This is also reminiscent of the
phenotype described for DM1 patient myoblasts in culture
(Furling et al., 2001; Timchenko et al., 2001). Importantly,
DM1 patient cells show reduced MyoD protein levels as
compared with control cells (Timchenko et al., 2001), sug-
gesting that the molecular defects that reduce MyoD levels in
GFP mut 3 -UTR cells may also compromise MyoD in pa-
tient cells. Exogenous MyoD is capable of rescuing the defects
seen in MyoD
 /  cells (Sabourin et al., 1999) and overriding
the negative effects of the mutant DMPK 3 -UTR RNA on
differentiation (Fig. 7). This is consistent with the idea that
spontaneous overexpression of MyoD provides the “resis-
tance” in mut 3 -UTR-res cells (Fig. 2). Because the differen-
tiation defect can be rescued by elevating MyoD levels, or
by adding exogenous myogenin, which acts downstream of
MyoD, we conclude that compromised MyoD levels are re-
sponsible for inhibiting myoblast differentiation.
Loss of MyoD function in GFP mut 3 -UTR cells is con-
sistent with the blunted induction of differentiation-specific
genes such as myogenin and p21. The expression of these
genes is regulated in part through E-boxes (Yee and Rigby,
1993; Halevy et al., 1995), providing evidence of a defect
in MyoD and/or Myf5 activity. Consistent with the lack of
activation of endogenous genes containing E-boxes, we
found that E-box–luciferase expression was not induced in
GFP mut 3 -UTR pool cells under differentiation condi-
tions (Fig. 4 C; Fig. 5 A). During the first 24 h in differentia-
tion media, the lack of E-box activation correlated with the
sharp reduction of MyoD protein levels. Elevating MyoD lev-
els in these cells restores the induction of myogenin (Fig. 7 C)
and E-box–luciferase (unpublished data). This suggests that
the amount of MyoD in GFP mut 3 -UTR pool cells is not
sufficient to initiate and/or sustain E-box–mediated gene ex-
pression, which explains why myogenin, p21, and other differ-
entiation-specific genes are not properly expressed.
Why can’t the normal levels of Myf5 up-regulate E-box
genes in these cells? Consistent with our results that Myf5
cannot compensate for the lack of MyoD, myoblasts derived
from adult MyoD
 /  mice show dampened up-regulation of
differentiation-specific genes despite a  10-fold up-regula-
tion of Myf5 (Sabourin et al., 1999). This indicates that
MyoD has essential functions that Myf5 is unable to per-
form. Additional studies have shown that during differentia-
tion of both C2C12 and primary mouse myoblasts, MyoD
is found exclusively in differentiating cells and Myf5 is ex-
pressed only in the cells that do not differentiate (Kitzmann
et al., 1998; Lindon et al., 1998). These observations argue
that proper MyoD expression and activity are absolutely re-
quired for myoblast differentiation.
How do mutant DMPK 3 -UTR transcripts 
compromise MyoD?
It is thought that mutant DMPK RNA disrupts cellular
processes by interacting aberrantly with RNA binding pro-
teins. The aggregation of DMPK transcripts in nuclear foci
could either activate or sequester proteins, leading to a vari-
Figure 8. A model for how mutant DMPK 3 -UTR transcripts 
reduce MyoD protein levels and disrupt C2C12 differentiation. 
(A) A schematic of steps involved in producing MyoD in C2C12 
myoblasts. MyoD, which is required for differentiation of adult 
myoblasts, ultimately initiates differentiation genes, such as myogenin, 
by binding E-boxes. (B) Potential steps where mutant DMPK 3 -UTR 
RNA (red knot in the nucleus) could interfere with MyoD protein 
production. MyoD mRNA transcription, stability, and transport are 
unaffected, but the mutant 3 -UTR RNA could alter splicing or 
processing of the MyoD transcript (1), RNA localization in the 
cytoplasm (2), translation efficiency (3), or protein stability (4). The 
end result is a reduction of MyoD protein levels, which fall below a 
critical threshold required to effectively activate gene expression 
and initiate differentiation. Mutant DMPK 3 -UTR transcripts compromise MyoD | Amack et al. 427
ety of downstream consequences. Characterization of one
such protein, CUGBP1, has shown that RNAs containing
expanded CUG repeats affect CUGBP1 function in both
mRNA splicing and translation (Philips et al., 1998; Tim-
chenko et al., 1999). Defects in any one of several processes
could account for the reduction of MyoD protein levels in
cells expressing the mutant DMPK 3 -UTR (Fig. 8). We
first tested MyoD expression at the RNA level and found
that transcription and mRNA stability are not affected in
the GFP mut 3 -UTR pool during the first 12 h in differ-
entiation media (Fig. 6). An intriguing possibility down-
stream of transcription was that MyoD transcripts get
“caught” in the nuclear RNA foci and are not transported
to the cytoplasm for translation. However, nuclear and cy-
toplasmic fractionation of RNA from GFP mut 3 -UTR
cells showed no evidence that MyoD mRNA was retained
in the nucleus (unpublished data). RNA splicing and/or
processing defects could reduce MyoD protein levels, but
gross changes in transcript length were not apparent on
Northern blots. Any splicing alterations would have to be
subtle and could not change the size or stability of the tran-
script. Other possibilities include mislocalization of MyoD
RNA in the cytoplasm, poor translation efficiency, and de-
creased MyoD protein stability (Fig. 8). Our cell culture
model will provide an excellent system to test each of these
possibilities and further characterize the trans effect on
MyoD protein levels.
The results presented here support the model shown in
Fig. 8 for how mutant transcripts disrupt C2C12 differenti-
ation. First, MyoD protein levels are compromised as a re-
sult of aberrant interactions between RNA binding proteins
and nuclear aggregates of the mutant DMPK 3 -UTR RNA.
Links between MyoD level and differentiation efficiency
suggest that there is a threshold level of MyoD required for
differentiation (Montarras et al., 1996; Kitzmann et al.,
1998). Our data suggest that during the first 24 h in differ-
entiation media, MyoD levels drop below the threshold that
is required to transactivate target genes. This time window
is thought to be critical for the induction of differentia-
tion genes that commit cells to differentiation. MyoD binds
E-boxes and induces several genes within 24 h of being acti-
vated (Bergstrom et al., 2002). For example, myogenin up-
regulation begins within 12 h of MyoD activation and is
maximal after 24 h (Bergstrom et al., 2002). In our model,
MyoD protein expression is reduced to levels that are insuf-
ficient to activate myogenin and other differentiation genes,
and in the absence of these gene products, cells fail to initiate
the differentiation program.
In conclusion, we have identified MyoD as a target of a
trans effect mediated by mutant DMPK 3 -UTR RNA. The
reduction of MyoD protein levels provides a molecular ex-
planation for why cells expressing mutant 3 -UTR tran-
scripts fail to differentiate. Future projects, some of which
are already underway, are designed to determine how the
mutant DMPK RNA compromises MyoD. In addition, as
demonstrated by the successful rescue of the differentiation
defect by retroviral expression of myogenin and MyoD, our
cell culture model may be useful in developing strategies to
override the effects of the mutant DMPK RNA. Under-
standing how mutant DMPK RNA causes deleterious effects
at the molecular level may provide insight into how muscle
defects arise in DM patients and how to correct them.
Materials and methods
Cell culture
C2C12 myoblasts were maintained at subconfluence in growth media con-
sisting of DME (Cellgro
®) plus 10% cosmic calf serum (HyClone). Stable
transfected GFP wt 3 -UTR and GFP mut 3 -UTR cells (described in
Amack and Mahadevan, 2001) were maintained in selective media con-
taining 0.5  g/ml G418 (GIBCO BRL). The generation of clone pools was
previously described (Amack and Mahadevan, 2001). To induce myoblast
differentiation, cells were grown to  90% confluence and then cultured in
differentiation media containing DME supplemented with 2% horse serum
(HyClone). Differentiation media was replaced every 24 h.
Retroviral infection
For transduction with retroviral vectors, cells were plated at low density
(2   10
5 cells) in 10-cm dishes. The next day, cells were exposed to 4 ml
of media harvested from confluent cells producing the retrovirus, supple-
mented with 8  g/ml polybrene (Sigma-Aldrich), for 3 h. 24 h later, the
cells were exposed to a second infection. Mock infections (referred to as
uninfected cells) were conducted in parallel using regular growth media
plus polybrene. For differentiation studies, infected and uninfected cells
were switched into differentiation media 1 d after the second infection.
The following retroviruses were used: LMDSN expressed MyoD (Wein-
traub et al., 1989); and JR-gal expressed LacZ (Wang et al., 1991). Media
containing the myogenin retrovirus was a gift from R. Ilaria (University of
Texas Southwestern, Dallas, TX).
Immunostaining and RNA FISH
To detect myosin heavy chain (MHC) expression, cells cultured in differenti-
ation media for 3 d were fixed in 4% paraformaldehyde for 15 min at room
temperature and stored in 70% ethanol at 4 C. Cells rehydrated in PBS were
incubated with MY32 primary antibody (Sigma-Aldrich) diluted in PBS  
1% BSA for 1 h at 37 C. After washing, cells were incubated with a Texas
red–conjugated secondary antibody (Jackson ImmunoResearch Laborato-
ries) for 1 h at 37 C. Nuclei were stained with DAPI (Sigma-Aldrich).
RNA FISH experiments were performed as previously described (Amack
et al., 1999). In brief, fixed cells were incubated with a CY3-conjugated
(CAG)10 oligonucleotide probe (Operon) diluted to 0.1  g/ml in RNA hy-
bridization buffer for 2 h at 37 C. After three washes in PBS, nuclei were
stained with DAPI.
Fluorescent signals were visualized using an Olympus IX 50 micro-
scope with epifluorescence. Pictures were taken with a SPOT II digital
camera (Diagnostic Instruments), and images were assembled using Adobe
Photoshop
® and Canvas (Deneba Systems) software.
Western blot analysis
Cells were lysed in 50 mM Hepes, pH 7.6, 150 mM NaCl, 10% glycerol,
1% Triton X-100, 1.5 mM MgCl2, 0.5 mM DTT, and 0.1 mM EDTA supple-
mented a with protease inhibitor cocktail (Roche). 50  g of total protein
was fractionated by SDS-PAGE and transferred onto a nitrocellulose mem-
brane (Schleicher & Schuell). Membranes were blocked overnight in PBS
containing 10% skimmed milk, and then incubated for 1–3 h with primary
antibodies diluted in PBS containing 1% BSA. The following primary anti-
bodies were used: MyoD (BD Biosciences), Myf5 (Santa Cruz Biotechnol-
ogy, Inc.), myogenin (Santa Cruz Biotechnology, Inc.), and dynein (Santa
Cruz Biotechnology, Inc.). After incubation with the primary antibody,
membranes were washed in PBS containing 0.3% Tween-20, and then in-
cubated with a secondary antibody conjugated to HRP (Santa Cruz Bio-
technology, Inc.) for 1 h. After several washes, proteins were detected us-
ing ECL reagents. Films were scanned and protein bands were quantified
using ImageQuant software (Molecular Dynamics). The Mann-Whitney
test was used for all statistical analyses.
Luciferase assays
The reporter plasmid pE-boxLuc was generated by subcloning a HinDIII-
XhoI fragment from p3R-CAT (Weintraub et al., 1990), which contains
three tandem “right” E-boxes from the muscle-specific creatine kinase en-
hancer inserted 5  of TK promoter sequences, upstream of the luciferase
gene in pTKLuc (a gift from E. Olson, University of Texas Southwestern).
pTKLuc serves as a control construct that contains the TK promoter and lu-
ciferase, but lacks E-boxes.428 The Journal of Cell Biology | Volume 159, Number 3, 2002
Control C2C12, GFP wt 3 -UTR pool, and GFP mut 3 -UTR pool
cells were transfected as previously described (Amack and Mahadevan,
2001) with pE-boxLuc and a plasmid conferring puromycin resistance, and
stable transfectants were selected in media containing 4  g/ml puromycin.
After selection, puromycin-resistant colonies (an average of  270 per
transfection) were trypsinized, combined, and analyzed as a collection of
independent transfection events. Visualization of GFP and RNA FISH ex-
periments demonstrated that transfected GFP wt 3 -UTR and GFP mut
3 -UTR cells retained expression of the 3 -UTR transcripts (not depicted).
These cells were grown in selective media containing both G418 and
puromycin. In parallel, each population of cells was separately transfected
with the control pTKLuc construct.
To measure luciferase, samples were prepared using the luciferase assay
system (Promega), and relative light units were determined by a MLX lumi-
nometer (Dynex Technologies). Raw relative light units were normalized
to protein concentration, which was measured using the Bio-Rad Labora-
tories protein assay. The amount of luciferase produced in proliferating
cells, which varied among the different stably transfected cell lines, was set
equal to one, and changes in luciferase expression during differentiation
were analyzed relative to these starting levels. To determine the fold
change in luciferase expression that was due strictly to the E-boxes, we
subtracted changes that were due to the TK promoter sequences, as ob-
served in cells transfected with the control pTKLuc construct. The fold in-
duction of E-box–mediated luciferase expression was analyzed in three in-
dependent differentiation experiments.
RNA analysis
Total RNA was prepared by lysing cells in 4 M guanidinium thiocyanate,
20 mM sodium acetate, pH 5.4, and 0.5% sarkosyl and then isolating RNA
by ultracentrifugation through a 5.7 CsCl density gradient. Northern and
RNA slot blots were generated and analyzed as previously described
(Amack and Mahadevan, 2001). Results were quantified using Im-
ageQuant software (Molecular Dynamics).
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